Fortitude Family Office’s Kymera Therapeutics KYMR Stock Holding History

Fortitude Family Office’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.58K	Hold	41	–	–	﹤0.01%	1617
2026 Q2	$4.7K	Hold	41	–	–	﹤0.01%	1104
2026 Q1	$3.42K	Buy	41 +20	+95%	+$1.58K	﹤0.01%	1075
2025 Q4	$1.63K	Buy	21 +3	+17%	+$203	﹤0.01%	1258
2025 Q3	$1.02K	Hold	18	–	–	﹤0.01%	1543
2025 Q2	$786	Buy	+18	New	+$620	﹤0.01%	1616

Other funds holding KYMR

KMWM

Keudell/Morrison Wealth Management Salem, Oregon $562M AUM 21.01% 1-Year Est. Return

NAM

NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Mather Group Chicago, Illinois $11.8B AUM 12.84% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

CIA

Cape Investment Advisory Mcdonough, Georgia $388M AUM 17.15% 1-Year Est. Return

Fortitude Family Office's KYMR Position: Q3 2026 in Review

Fortitude Family Office held its Kymera Therapeutics (KYMR) position steady in Q3 2026 at 41 shares worth $4.58K. The position accounts for ﹤0.01% of the portfolio, ranked #1617.

Fortitude Family Office first reported a position in KYMR in Q2 2025 and has held it in 6 quarters since. The position peaked at $4.7K in Q2 2026. 14 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

Fortitude Family Office held 41 shares of Kymera Therapeutics worth $4.58K as of Q3 2026.
Fortitude Family Office left its Kymera Therapeutics share count unchanged in Q3 2026.
Kymera Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #1617 holding.
Fortitude Family Office first reported a position in Kymera Therapeutics in Q2 2025 and has held it in 6 quarters since.
Fortitude Family Office's Kymera Therapeutics position peaked at $4.7K in Q2 2026.
14 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.